TRW KNOWLEDGE · LEGAL INFORMATION
Pharmaceutical Regulatory Law in Bangladesh: Practical Guide for Companies and In-house Counsel
This guide explains the practical role of a pharmaceutical regulatory lawyer in Bangladesh, summarizes the primary statutory and international instruments often referenced in this sector, and sets out a compliance checklist, risk-management considerations, and next steps for companies engaged in manufacture, import, export and distribution of pharmaceutical products.
Introduction
This guide explains what pharmaceutical regulatory legal work commonly covers in Bangladesh, the regulatory frameworks and international instruments that regularly arise in practice, and practical steps companies and their in-house teams can take to reduce regulatory risk. It is based on the regulatory topics and instruments commonly raised for pharmaceutical businesses operating in Bangladesh and on the legal-service areas described in the source material. The guidance below is informational and conditional: exact obligations and procedures can depend on facts not present here and may change, so always check official texts and seek tailored legal advice.Why specialised legal support matters in the pharmaceutical sector
The pharmaceutical industry in Bangladesh operates under multiple overlapping regimes: public-health regulation, customs and trade rules, financial and foreign-exchange controls, and international trade and documentary instruments. A regulatory lawyer focused on pharmaceuticals helps translate these regimes into operational steps — for licensing and product registration, for cross-border trade, for contract drafting with suppliers and distributors, and for responding to regulatory enquiries or disputes.Typical areas where legal input is sought
- Product licensing and registration with the Department of Drug Administration (DDA).
- Customs clearance, tariff classification and customs valuation for raw materials and finished goods under the Customs Act 1969 and national import-export policy.
- Compliance with import and export policy documents such as the Import Policy Order 2021-2024 and Export Policy 2024-2027.
- Trade finance advice relating to letters of credit and guarantees under instruments like UCP 600 and URDG 758.
- Foreign-exchange and banking compliance under the Foreign Exchange Regulation Act 1947 and the Bank Company Act 1991.
- Security interests over movable assets and receivables that may involve the Secured Transactions (Movable Property) Act 2023.
- Regulatory investigations, product recalls, administrative appeals and litigation, including potential proceedings before administrative tribunals and higher courts such as the Bangladesh Supreme Court.
Core national and international frameworks to be aware of
Below is a concise summary of the principal instruments referenced in the source material. Each entry explains the practical relevance rather than reproducing statutory text. Where a particular topic requires precise interpretation (licensing timelines, documentation checklists, or procedural steps) you should consult the original statutory or regulatory instruments and the relevant authority.| Framework | Relevance to pharmaceutical activity | Typical legal work |
|---|---|---|
| Customs Act 1969 | Primary domestic law for import/export clearance, duty assessment and customs procedures. | Advising on tariff classification, customs valuation, documentation for release and responding to detention or valuation disputes. |
| Import Policy Order 2021-2024 | Sets licensing and documentary requirements for permitted imports during the policy period. | Determining whether materials or finished products require special licences or approvals and preparing license applications. |
| Export Policy 2024-2027 | Regulates export procedures, documentation and any incentives or restrictions applicable in the policy period. | Advising on export documentation, eligibility for incentives and compliance with any restricted or prohibited lists. |
| Foreign Exchange Regulation Act 1947 & Bank Company Act 1991 | Govern foreign currency transactions, remittances and banking operations relevant to cross-border payments and investments. | Guidance on foreign-exchange compliance, remittance documentation and bank regulatory expectations for trade finance. |
| Secured Transactions (Movable Property) Act 2023 | Modernises creation and enforcement of security interests over movable property, which can affect financing and supply-chain security. | Structuring security packages, registering security interests and advising on enforcement pathways subject to statutory rules. |
| INCOTERMS 2020; UCP 600; URDG 758 | International commercial terms and documentary-credit rules that govern allocation of risks and documentary compliance in cross-border sales and trade finance. | Drafting and negotiating contracts using correct INCOTERMS; advising on documentary compliance under letters of credit or demand guarantees. |
| WTO and UNCITRAL instruments | International trade law principles and arbitration standards that form part of the legal backdrop for cross-border contracts and dispute resolution. | Advising on contractual dispute-resolution clauses and international trade law considerations where multijurisdictional issues arise. |
Licensing and regulatory submissions: practical considerations
Licensing and product registration are central to market access. In Bangladesh, the Department of Drug Administration is the regulatory authority commonly responsible for approvals related to pharmaceuticals. A regulatory lawyer’s role is to translate statutory and administrative requirements into an executable plan for the business.Practical steps for licensing and registration
- Map the product lifecycle and identify regulatory touchpoints: raw-material imports, active pharmaceutical ingredient (API) approvals, finished-product registration, labelling and pharmacovigilance obligations.
- Prepare a document register that tracks applications, certificates of analysis, manufacturing licences, GMP-related documents, and correspondence with regulators.
- Confirm whether import licences or permits are required under the current Import Policy Order and factor lead-times into procurement planning.
- Build a record-keeping system to respond quickly to regulatory queries about batch release, adverse events, or product traceability.
- Where foreign investment or cross-border payments are involved, check foreign-exchange formalities and banking documentation early in the transaction process.
Cross-border trade, customs and trade finance: operational checkpoints
Pharmaceutical companies often rely on timely cross-border movement of APIs, excipients and finished products. Delays or misclassification at customs, documentary non-compliance under letters of credit, or incorrect use of INCOTERMS can all create commercial and regulatory problems. A regulatory lawyer coordinates with logistics, procurement, customs brokers and banking partners to reduce these risks.Key operational checkpoints
- Classify goods correctly for customs using the Harmonized System headings and document the commercial rationale for classification.
- Confirm whether particular materials are subject to import restrictions or require licences under the Import Policy Order 2021-2024.
- Check documentary requirements under trade-finance instruments (for example UCP 600 for letters of credit or URDG 758 for demand guarantees) to avoid discrepancies in presentation.
- Agree INCOTERMS 2020 terms in sales contracts that reflect the intended allocation of delivery risk, insurance and transport responsibility.
- Document foreign-exchange transactions to satisfy bank compliance checks under the Foreign Exchange Regulation Act 1947.
Risk management, recalls and regulatory investigations
Regulators may initiate investigations or take enforcement action where public-health risks or non-compliance are identified. Clear internal processes and rapid legal involvement can materially affect outcomes.Recommended internal procedures
- Maintain an internal escalation protocol that identifies legal, regulatory and quality contacts to be notified immediately when a quality concern arises.
- Preserve relevant records (batches, shipping documents, test reports) and log steps taken from discovery to remedial action.
- Coordinate communication to regulators with legal review to manage admissions and limit unintended statements.
- Prepare a recall plan that sets out responsibilities, timelines and public-communication templates; update it after any simulation exercises or real events.
- Consider early engagement with advisors experienced in administrative appeals and litigation so that potential further steps are understood and reserved.
Contracting and commercial arrangements
Commercial contracts — distribution agreements, manufacturing agreements, supply contracts, and agency arrangements — should be drafted to reflect regulatory realities. Common issues include responsibility for product registration and labelling, indemnities for regulatory non-compliance, allocation of recall costs, and dispute-resolution clauses that take into account possible cross-border elements.Contract drafting items to consider
- Who bears responsibility and cost for obtaining and maintaining regulatory approvals?
- How will adverse regulatory developments (for example withdrawal of a licence) affect supply and pricing?
- Which INCOTERM applies, and how does it interact with logistics and insurance?
- Which dispute resolution forum and rules will apply if there is a commercial dispute; consider whether arbitration or domestic litigation is appropriate.
- Include practical cooperation clauses for regulatory inspections and product information sharing in the case of adverse events.
Litigation and dispute resolution
When disputes arise — whether regulatory, contractual or intellectual-property related — there are multiple pathways for resolution. The source material notes representation before administrative tribunals and courts including the Bangladesh Supreme Court. The choice of forum and dispute-resolution mechanism should be driven by the dispute’s nature and the relief sought.Considerations when selecting a dispute-resolution route
- Timing and interim relief needs: some remedies are only available through domestic courts or administrative bodies.
- Confidentiality and enforceability: arbitration can offer confidentiality and cross-border enforceability in many situations, while court judgments are enforced through domestic procedures.
- Technical expertise: disputes that turn on technical regulatory or scientific issues may benefit from expert determination or technical advisory panels within the chosen procedure.
- Costs: weigh potential exposure to costs against speed and certainty of outcome.
Practical compliance checklist for pharmaceutical companies
The checklist below is a practical tool to help teams identify common compliance items. It is not exhaustive and should be tailored to your specific products and operational footprint.- Identify all regulatory authorities with jurisdiction over your product (e.g., DDA) and maintain current contact details and portal access for submissions.
- Maintain an updated register of licences and expiry dates for manufacturing, import and marketing authorisations.
- Document the source and classification of all imported APIs and raw materials; keep supplier declarations and certificates of analysis on file.
- Confirm whether imported materials are subject to special import licences under the Import Policy Order 2021-2024 or other policy instruments and secure them in advance.
- Agree commercial terms (INCOTERMS 2020) in all sales and purchase contracts and ensure logistics partners understand these terms.
- For transactions using letters of credit or demand guarantees, review documentary requirements early to avoid discrepancies under UCP 600 and URDG 758.
- Document the legal basis for customs valuation and classification to be able to respond to customs queries under the Customs Act 1969.
- Keep foreign-exchange transaction records and bank correspondence ready for compliance checks under the Foreign Exchange Regulation Act 1947.
- Register and monitor any security interests under the Secured Transactions (Movable Property) Act 2023 where relevant to financing arrangements.
- Prepare a recall and communications plan and test it periodically with internal and external stakeholders.
- Establish a schedule to review policy documents such as the Import Policy Order and Export Policy when new versions are published.
About our legal service approach
We describe service areas and practical steps rather than promising outcomes. TRW Law Firm is a full-service international law firm based in Dhaka. We bring together 220+ lawyers and legal professionals. Our approach emphasises coordination between regulatory, commercial and litigation teams to provide coherent advice across the full lifecycle of a pharmaceutical product.How to scope and budget for regulatory work
Scoping regulatory work typically requires an initial fact-finding phase to understand the product, sourcing and distribution model. A preliminary scope will usually cover:- a review of licences and registrations currently held;
- a gap analysis against anticipated regulatory submissions;
- an assessment of customs, trade-finance and foreign-exchange implications for planned transactions;
- risks that may require contingency planning such as recalls or regulatory queries.
Next practical steps and resources
If you are preparing market entry or planning changes to an existing supply chain, consider these next steps:- Gather all existing licences, registrations and material contracts and prepare a consolidated register for review.
- Identify the origin and tariff classification of materials you intend to import and flag any items that may be subject to import restrictions under the Import Policy Order 2021-2024.
- Review your documentary requirements under any letters of credit or guarantees and confirm the applicable UCP 600 or URDG 758 provisions with your bank.
- Engage legal counsel for a gap analysis and a practical compliance plan tied to procurement and production timelines.
FAQ
1. What specific licences are required to import APIs and finished pharmaceutical products into Bangladesh?
That depends on the nature of the materials and the current regulatory instruments in force. The Import Policy Order 2021-2024 sets out categories of imports that require licence or permit. In practice you should verify whether the raw materials or finished goods fall into categories that need specific import licences, and cross-check any DDA requirements for APIs or finished products. Because policies and classifications can change, confirm the current position with the regulatory authority or through legal review before shipment.2. How do INCOTERMS 2020, UCP 600 and URDG 758 interact in pharmaceutical transactions?
INCOTERMS 2020 define allocation of delivery responsibilities, risks and costs between buyer and seller. UCP 600 governs documentary letters of credit while URDG 758 governs demand guarantees; both prescribe how banks will treat presented documents. The practical interaction is that your sales contract should align INCOTERMS with the documentary requirements in the letter of credit or guarantee to avoid discrepancies at presentation. Legal counsel typically reviews both to ensure the operational instructions to banks and logistics providers are consistent with the commercial terms.3. If customs detains a shipment, what are the immediate legal steps?
Immediate steps generally include gathering all commercial and shipping documentation, issuing a clear instruction to your customs broker to request the grounds of detention, and engaging legal counsel to review classification and valuation. Under the Customs Act 1969 there are administrative steps and opportunities to challenge determinations, but exact timelines and remedies depend on the facts of the detention. Early preservation of records and rapid coordination with customs and legal advisors is important.4. When should a company consider registering a security interest under the Secured Transactions (Movable Property) Act 2023?
Consider registration where financing arrangements rely on security over inventories, receivables or other movable assets. Registration can affect priority against other creditors and may be required by lenders as a condition of financing. The business should evaluate whether registration helps secure credit lines or supplier-finance arrangements and seek advice on the correct steps and documentation to perfect a security interest under the Act.5. What are common pitfalls with letters of credit for pharmaceutical imports?
Common pitfalls include documentary discrepancies (e.g., mismatches in description, quantities, or dates), failure to align INCOTERMS to the documentary presentation, and insufficient coordination between suppliers and banks on acceptable documents. Because banks apply UCP 600 standards strictly, it is prudent to prepare a documentary checklist matched to the letter of credit and to allow time for the supplier and bank to resolve anticipated documentary issues before shipment.6. How can a company prepare for a regulatory inspection or product recall?
Preparation includes maintaining up-to-date quality records, having a clear recall plan with assigned responsibilities, preserving batch-level documentation and test results, and creating an internal communications protocol that involves legal counsel early. If there is a potential public-health incident, coordinate communications with regulators and legal advisors to ensure factual reporting while protecting legal interests. Run periodic simulations to identify gaps.7. Are WTO and UNCITRAL rules directly enforceable in domestic disputes?
WTO and UNCITRAL instruments often influence international trade practice and arbitration but whether they are directly enforceable depends on domestic law and treaty implementation. In contractual or arbitration contexts parties commonly refer to UNCITRAL rules or to principles derived from international trade law; however, domestic courts and tribunals apply national law and procedure, so the practical impact will be case-specific.Final notes and how to proceed
This guide summarises practical legal considerations drawn from the regulatory instruments and service areas commonly raised for pharmaceutical businesses operating in Bangladesh. It does not substitute for a review of primary statutory texts or a tailored legal opinion. If you are preparing an application, planning cross-border procurement, or facing a regulatory or customs issue, gather your product and transaction documents and consider an initial diagnostic meeting.For more information about our services and how we work with clients in regulated industries, see /our-practices/ and /services/. To learn about the firm and key contacts see /our-firm/. To discuss a specific matter, please use /contact/, book a time directly at Book consultation or email info@trw.org.Continue the conversation
For further context and a tailored discussion of the facts, documents and current legal position, the following TRW resources may be useful:CONTINUE EXPLORINGConnected
Connected
legal insight.
Let’s discuss
the detail.
For a focused conversation with TRW, book a consultation or contact the firm directly.Book consultation →info@trw.org